Cytophage Provides Update on Bacteriophage Human Trial at The Ottawa Hospital

Winnipeg, [April 2nd, 2024]. Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”) is pleased to provide an interim update on the recently completed human trial at The Ottawa Hospital where Cytophage bacteriophages were used to treat a patient with an antibioticresistant prosthetic joint infection (see press release from March 1st, 2024). The patient had previously undergone 15 surgeries and was facing the potential amputation of her leg at the waist. She was treated with Cytophage phages for several weeks, via both direct injection and through an IV line, and the Company is happy to report that according to her physician, infectious diseases clinician-scientist Dr. Marisa Azad (Principal Investigator), her condition is steadily improving with inflammation in her body decreasing.

We can win the war against battlefield infection.
Cytophage was selected for the Defense Innovation Award 2019.

Winner of 2018 Nutreco Feed Tech Challenge
For our breakthrough innovation to help feed the world.

Swine Bacteriophage

We’re helping farmers meet the need and the demand for a healthier food chain.

Funded in part by the Canada and Manitoba governments through the Canadian Agricultural Partnership – Ag Action Manitoba Program. Learn more

Cytophage Technologies Ltd. © 2019